Alpha Cognition Inc. (ACOG)
NASDAQ: ACOGHealthcareBiotechnologyUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
ACOG stock chart
Technical analysisKey statistics
All statistics- Market cap
- $198.37M
- EPS (TTM)
- -$1.32
- Dividend yield
- None
- 52-week range
- 4.50 – 10.14
- Day range
- 8.58 – 9.10
- Volume / Avg
- 269.67K / 118.91K
- Beta
- —
- Shares outstanding
- 22.04M
52-week range
ACOG stock today
Alpha Cognition (ACOG) closed at $9.00 on Nov 20, up 1.69% (+$0.15), versus the S&P 500's 3.70% decline. Volume was 2.3x the average at 269.67K shares, a sign of unusually heavy trading. At this level, ACOG sits in the middle of its 52-week range of $4.50 to $10.14: 11.2% below the high, set on Aug 24, 2026 and 100.0% above the low.
ACOG is up 38.5% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 56.5%. Alpha Cognition has posted a net loss over the last twelve months (EPS of -$1.32), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Alpha Cognition
Company profileAlpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company's commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimer's disease. Its pre-clinical development programs comprise ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer's disease; ALPHA-1062 sublingual formulation; ALPHA-1062 intranasal formulation for the treatment of cognitive impairment with mild traumatic brain injury; and ALPHA-0602, ALPHA-0702, and ALPHA-0802 programs for the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis disease and spinal muscular atrophy.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. Michael E. McFadden B.B.A.
- Headquarters
- Grapevine, TX
- Employees
- 71
- Website
- alphacognition.com
Financial highlights
Full financialsIn fiscal 2025, Alpha Cognition generated $10.2 million in revenue. Alpha Cognition reported a net loss of $20.7 million, compared with a loss of $14.8 million a year earlier. Gross margin was 94.1% and operating margin -221.7%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Revenue | $10.22M | — | — |
| Growth | — | — | — |
| Net income | $-20.67M | $-14.79M | $-13.76M |
| EPS (diluted) | $-1.18 | $-2.04 | $-3.84 |
Analyst forecast
ForecastConsensus (6 analysts)
strong_buy
Avg. price target
$18.20+102.22%
- Strong buy 3
- Buy 3
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 11, 2026
- EPS actual vs est.
- $-0.30 vs $-0.33
- Surprise
- +9.09%
ACOG news
All ACOG news- Is Novartis (NVS) Outperforming Other Medical Stocks This Year?NasdaqNVS, ACOG
- Alpha Cognition (ACOG) Q3 2026 Earnings Call TranscriptNasdaq
- Alpha Cognition Inc. Reports Third Quarter 2026 Financial Results and Provides Operational UpdateBusiness Wire
- Halozyme Therapeutics (HALO) Tops Q3 Earnings and Revenue EstimatesNasdaqHALO, ACOG
- Alpha Cognition to Report Third Quarter 2026 Financial Results and Provide Business UpdateBusiness Wire
Indexes, lists and sector
Appears in lists
Largest Healthcare stocks
Alpha Cognition stock FAQ
What is Alpha Cognition's stock price today?
ACOG last traded at $9.00 as of Nov 20, 4:00 PM EST, up 1.69% on the day. Prices are delayed at least 15 minutes.
Who is Alpha Cognition's CEO?
Mr. Michael E. McFadden B.B.A. is the chief executive officer of Alpha Cognition Inc., which has about 71 employees.
What is the ACOG 52-week high?
The 52-week high for ACOG is $10.14 and the 52-week low is $4.50. The stock is currently 11.2% below its high.